L Gossec1, J S Smolen2, S Ramiro3, M de Wit4, M Cutolo5, M Dougados6, P Emery7, R Landewé8, S Oliver9, D Aletaha10, N Betteridge4, J Braun11, G Burmester12, J D Cañete13, N Damjanov14, O FitzGerald15, E Haglund16, P Helliwell17, T K Kvien18, R Lories19, T Luger20, M Maccarone21, H Marzo-Ortega7, D McGonagle7, I B McInnes22, I Olivieri23, K Pavelka24, G Schett25, J Sieper26, F van den Bosch27, D J Veale28, J Wollenhaupt29, A Zink30, D van der Heijde3. 1. Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), Paris, France Department of rheumatology, AP-HP, Pitié Salpêtrière Hospital, Paris, France. 2. Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria Second Department of Medicine, Hietzing Hospital, Vienna, Austria. 3. Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands. 4. EULAR, representing People with Arthritis/Rheumatism in Europe (PARE), London, UK. 5. Research Laboratory and Clinical Division of Rheumatology, Department of Internal Medicine, University of Genova, Viale Benedetto, Italy. 6. Medicine Faculty, Paris Descartes University, Paris, France Rheumatology B Department, APHP, Cochin Hospital, Paris, France. 7. Leeds NIHR Musculoskeletal Biomedical Research Unit, LTHT, Leeds, UK Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. 8. Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands Atrium Medical Center, Heerlen, The Netherlands. 9. North Devon, UK. 10. Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria. 11. Rheumazentrum Ruhrgebiet, Herne and Ruhr-Universität Bochum, Herne, Germany. 12. Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Germany. 13. Arthritis Unit, Department of Rheumatology, Hospital Clínic and IDIBAPS, Barcelona, Spain. 14. Belgrade University School of Medicine, Belgrade, Serbia. 15. Department of Rheumatology, St. Vincent's University Hospital and Conway Institute, University College Dublin, Dublin, Ireland. 16. Section of Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden Sweden and School of Business, Engineering and Science, Halmstad University, Halmstad, Sweden. 17. Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK. 18. Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. 19. Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, KU Leuven, Belgium Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium. 20. Department of Dermatology, University Hospital Münster, Münster, Germany. 21. A.DI.PSO. (Associazione per la Difesa degli Psoriasici)-PE.Pso.POF (Pan European Psoriasis Patients' Organization Forum), Rome, Italy. 22. Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK. 23. Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy. 24. Institute and Clinic of Rheumatology Charles University Prague, Czech Republic. 25. Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany. 26. Department of Rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany. 27. Ghent University Hospital, Ghent, Belgium. 28. Centre for Arthritis and Rheumatic Disease, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland. 29. Schoen Klinik Hamburg, Rheumatology and Clinical Immunology, Hamburg, Germany. 30. Department of Rheumatology and Clinical Immunology, German Rheumatism Research Centre Berlin, Charité-University Medicine Berlin, Germany.
Abstract
BACKGROUND: Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. METHODS: A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. RESULTS: The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL)12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. CONCLUSIONS: These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. METHODS: A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. RESULTS: The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL)12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. CONCLUSIONS: These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Philip Mease; Ernest Choy; Peter Nash; Chrysostomos Kalyvas; Matthias Hunger; Luminita Pricop; Kunal K Gandhi; Steffen M Jugl; Howard Thom Journal: Eur J Rheumatol Date: 2018-07-01
Authors: Caterina Palleria; Luigi Iannone; Christian Leporini; Rita Citraro; Antonia Manti; Maurizio Caminiti; Pietro Gigliotti; Rosa Daniela Grembiale; Massimo L'Andolina; Giuseppe Muccari; Maria Diana Naturale; Domenico Olivo; Giuseppa Pagano Mariano; Roberta Pellegrini; Giuseppe Varcasia; Karim Abdalla; Emilio Russo; Francesco Ursini; Giovambattista De Sarro Journal: PLoS One Date: 2018-10-24 Impact factor: 3.240
Authors: Karine Toupin-April; Jennifer L Barton; Liana Fraenkel; Alexa Meara; Linda C Li; Peter Brooks; Maarten de Wit; Dawn Stacey; France Légaré; Beverley Shea; Anne Lyddiatt; Cathie Hofstetter; Robin Christensen; Marieke Scholte Voshaar; Maria E Suarez-Almazor; Annelies Boonen; Tanya Meade; Lyn March; Janet Elizabeth Jull; Willemina Campbell; Rieke Alten; Suvi Karuranga; Esi M Morgan; Ayano Kelly; Jessica Kaufman; Sophie Hill; Lara J Maxwell; Dorcas Beaton; Yasser El-Miedany; Shikha Mittoo; Susan J Bartlett; Jasvinder A Singh; Peter S Tugwell Journal: J Rheumatol Date: 2019-02-01 Impact factor: 4.666